22-644 Phase I
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
Search Cancer Clinical Trials
Mass General Brigham Cancer Institute offers patients access to a wide variety of
clinical trials of promising new therapies. Use the search tool to find open protocols
for your type of cancer.
9 results
26-117 Phase I
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-BCMA CAR-T Cells in Patients with Relapsed and Refractory Multiple Myeloma
26-145 Phase II
A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants with Relapsed or Refractory Multiple Myeloma
24-727 Phase II
A phase 2 study of elranatamab in combination with isatuximab (ELISA) in relapsed and refractory multiple myeloma
25-740 Phase II
A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
24-044 Phase II
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
25-319 Phase II
A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma DURGA-1
23-183 Phase II
A phase II study of ISABELA: isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
25-320 Phase I
MAGENTA: Phase I study of mezigdomide and talquetamab in relapsed and refractory multiple myeloma
Showing 1 - 10 of 9 results